首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 93 毫秒
1.
目的:了解福建省汉族人儿茶酚氧位甲基转移酶(COMT)1947位点基因多态性分布,为探讨该基因多态性与疾病的相关性及对药物代谢影响提供遗传背景资料。方法:应用聚合酶链反应技术-限制性内切酶分析检测了166名福建汉族正常人的COMT基因1947位点多态性,并比较了不同人群之间的基因型与等位基因频率。结果:福建汉族人COMT1947位点基因型(GG,GA和AA)分布频率分别是58.4%,36.7%,4.8%。COMT1947位点等位基因频率G和A分别是77%和23%。福建汉族人COMT1947位点的基因型分布和等位基因频率同肯尼亚人、日本人、台湾地区汉族人群比较差异无显著性,与美国、英国、芬兰和东南亚人比较,差异有极显著性CP〈0.01)。福建汉族人COMT的GG纯合型显著高于美国、英国、芬兰和东南亚人群;而AA纯合型显著低于美国、英国、芬兰和东南亚人群。结论:福建汉族人COMT1947位点基因多态性分布不同于某些地区的人群,具有种族差异。  相似文献   

2.
攻击行为与儿茶酚胺氧位甲基转移酶基因多态性研究   总被引:2,自引:0,他引:2  
目的:探讨精神疾病伴发的攻击行为与儿茶酚胺氧位甲基转移酶(catechol-0-methyltransferase,COMT)基因多态性的关系。方法:研究组(有攻击行为)43例,疾病对照组41例。健康对照组156例。采用聚合酶链反应-限制性片段长度多态性(PCR-KFLP)技术分析COMT基岗多态性。结果:①研究组的COMT基因型与健康对照组之间的差异有统计学意义。②研究组与疾病对照组之间的差异无统计学意义。③等位基因A携带患者在疾病症状(敌对性、情感平淡)及认知功能方面存在差异。结论:精神疾病患者其COMT基因多态性及等位基因分布频率与健康对照者不同。等位基因A携带患者的症状表现不同。攻击行为与COMT基因多态性无相关性。  相似文献   

3.
目的 分析性别与儿茶酚氧位甲基转移酶(COMT)活性之间的相关性.方法 建立测定红细胞COMT活性的高效液相色谱-电化学(HPLC-ECD)法,测定166名健康汉族志愿者红细胞COMT活性,分析性别与COMT活性之间的相关性;采用聚合酶链反应-限制性酶切片段长度多态性方法对志愿者COMT基因1947位点进行基因分型,进一步分析该位点不同基因型组内性别和COMT活性相关性.结果 建立的测定红细胞COMT活性的HPLC-ECD法准确、灵敏、重现性好,可满足测定需要.84名男性COMT活性为(1.347±0.621)pmol·mg-1·min-1,82名女性为1.255±0.473pmol·mg-1·min-1 ,两者差异无统计学意义(P>0.05);COMT基因1947位点G/G、G/A和A/A基因型组内男性和女性COMT活性差异也无统计学意义(P>0.05).结论 性别对COMT活性无明显影响.  相似文献   

4.
目的测定正常中国人群红细胞儿茶酚氧位甲基转移酶(COMT)活性浓度值,为研究COMT活性变化在疾病诊断中的应用提供依据。方法采用高效液相色谱法测定279名正常健康人(其中男性134例,女性145例)红细胞中COMT的活性浓度,用SPSS统计软件对性别间测定结果进行检验比较。结果男性和女性红细胞中COMT活性浓度分别为:(16.5±7.4)、(15.5±5.3)nmol.mL RBC-1.h-1。活性频率分布男性在6.0~37.4nmol.mL RBC-1.h-1,女性为5.4~37.2 nmol.mL RBC-1.h-1,男女之间COMT活性浓度的差异无统计学意义(P>0.05)。结论本法灵敏,简便,准确,重复性好,且测定结果与国外一些报道一致,适用于临床应用测定研究。本结果可作为中国健康人红细胞COMT活性正常值及今后研究的重要参考数据。  相似文献   

5.
目的研究儿茶酚-O-甲基转移酶(COMT)基因Val158Met多态性与乳腺癌易感性的关系。方法用人工修饰双等位基因特异性引物结合SYBR Green I荧光聚合酶链式反应法对96例乳腺癌患者(试验组)和116例健康志愿者(对照组)进行COMT Val158Met基因分型,分析2组各基因型和等位基因分布频率的差异。结果试验组和对照组的COMT Val158Met G等位基因分别为65.10%和71.98%,A等位基因分别为34.90%和28.02%,差异均无统计学意义(均P>0.05)。试验组和对照组的COMT Val158Met G/G野生纯合子基因型分布频率分别为38.54%和54.31%,A/G杂合子基因型分布频率分别为53.13%和35.34%,差异均有统计学意义(均P<0.05)。试验组和对照组的A/A突变纯合子基因型分布频率分别为8.33%和10.35%,差异无统计学意义(P>0.05)。相对于G/G基因型,试验组A/G基因型增加患乳腺癌风险(风险度为2.118,95%CI为1.189~3.744)。结论 COMT Val158Met基因多态性可能与乳腺癌易感性有关。  相似文献   

6.
目的:建立高效液相色谱-电化学法测定人体红细胞儿茶酚氧位甲基转移酶(COMT)活性。方法:以S腺苷-L-甲硫氨酸(SAM)为甲基供体,3,4-二羟基苯甲酸(DBA)为酶反应底物,COMT催化DBA生成扣羟基-3-甲氧苯甲酸(4-OH-3-MBA),高氯酸沉淀蛋白后直接进样,电化学检测4-OH-3-MBA;以每毫克蛋白每分钟生成的4-OH-3-MBA的pmol数表示COMT活性。色谱柱为Nova-pak C18(3.9mm&#215;150mm,4.0μm);流动相为0.1mol&#183;L^-1磷酸二氢钠缓冲液(内含EDTA0.15mmol&#183;L^-1)-甲醇(85:15),pH3.2,流速0.8mL&#183;min^-1,柱温25℃;工作电位+900mV。结果:4-0H-3-MBA在0.2~6μmol&#183;L^-1范围内线性良好,r=0.9997(n=6),4-OH-3-MBA最低检测浓度为0.02μmol&#183;L^-1(S/N≥3);4-OH-3-MBA0.2,2,6μmol&#183;L^-1浓度的日内、日间精密度RSD在1.09%~7.71%之间,回收率在96.0%~100.3%之间。结论:本法准确、灵敏、简便,适于红细胞COMT活性测定。  相似文献   

7.
目的将儿茶酚胺氧位甲基转移酶基因(COMT)克隆到原核表达载体进行可溶性表达,制备纯化COMT蛋白,为深入研究COMT的功能提供材料。方法运用分子生物学方法构建融合表达质粒Pet22b+-COMT。将Pet22b+-COMT转入E.coli BL21(DE3)表达菌株,利用IPTG诱导表达,并用亲和色谱纯化COMT。结果经测序分析成功构建了融合表达质粒Pet22b+-COMT。COMT基因在E.coli BL21(DE3)中表达相对分子质量约为28000的蛋白质,纯化后,COMT蛋白的纯度大于90%。结论COMT基因在原核中得到良好的表达,得到了纯度较高的蛋白质,为酶学活性研究奠定了基础。  相似文献   

8.
目的探讨胎盘中儿茶酚-O-甲基转移酶(COMT)单核苷酸多态性与子痫前期遗传易感性的关系。方法采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)技术,对138例子痫前期患者胎盘组织(子痫前期组)和126例正常晚期妊娠妇女胎盘组织(对照组)的COMT基因第4号外显子第158位密码子G与A的多态性进行分析,分析COMT单核苷酸多态性与子痫前期发生风险的关系。结果子痫前期组COMT基因型频率:野生型(GG)、杂合子(GA)、突变纯合子(AA)分别为58.7%、34.8%、6.5%,对照组分别为61.9%、33.3%、4.8%,两组比较差异无统计学意义(P〉0.05)。子痫前期组等位基因频率G、A分别为76.1%、23.9%,对照组分别为78.6%、21.4%,两组比较,差异无统计学意义(P〉0.05)。结论 COMT基因第158/108位密码子的单核苷酸多态性与子痫前期的发病及病情轻重程度无相关性。突变基因型并没有增加子痫前期的发病风险。  相似文献   

9.
目的:探讨巯嘌呤甲基转移酶(TPMT)基因多态性联合红细胞中硫鸟嘌呤核苷酸(6-TGNs)血药浓度监测在硫唑嘌呤治疗炎症性肠病中的临床应用,为实施个体化治疗方案提供参考。方法:选取临床确诊为炎症性肠病的患者,采用PCR扩增、焦磷酸基因测序法技术检测其TPMT基因第7外显子G460A和第10外显子A719G的2个多态性位点;应用高效液相色谱法测定患者红细胞(RBC)中6-TGNs浓度。结果:15例患者TPMT*3基因均为野生型,未发现突变;首次检测的6-TGNs浓度为 147.31~875.26 pmol/L(8×10^8)RBC,服用相同剂量的患者个体差异较大。结论:TPMT基因多态性检测有助于预测硫唑嘌呤治疗炎症性肠病的骨髓毒副作用,6 TGNs浓度测定有助于药物剂量的调整,两者联合应用可为接受硫唑嘌呤治疗的炎症性肠病患者的个体化治疗提供参考依据。  相似文献   

10.
硫唑嘌呤属于硫嘌呤类药物,是一种免疫抑制药。硫嘌呤甲基转移酶(thiopurine S-methyltransferase,TPMT)是参与硫唑嘌呤代谢的重要酶,TPMT的基因多态性是导致个体间用药差异的重要因素。TPMT基因遗传多态性导致酶活性存在个体差异,从而使接受硫唑嘌呤治疗的人群表现出不同的疗效和药物不良反应。TPMT的遗传多态性能够影响到TPMT酶的活性,而不同TPMT活性的患者在服用硫唑嘌呤后的药效学不同。越来越多的研究证实,在服用硫唑嘌呤之前进行基因型检测,针对不同TPMT活性的患者进行硫唑嘌呤个体化用药指导,可以有效地提高疗效,降低药物不良反应。本研究综述了基于TPMT基因多态性的硫唑嘌呤个体化用药治疗现状,通过讨论TPMT基因型指导下对不同患者服用硫唑嘌呤后的临床结局的影响,以及精准用药的建议,尤其关注了中国人群中TPMT用药的研究现状,以期为不同人群进行硫唑嘌呤治疗提供用药建议。  相似文献   

11.
12.
目的探讨帕罗西汀合并喹硫平治疗强迫症的临床效果和不良反应。方法将符合入组条件的60例强迫症患者随机分为研究组和对照组,每组30例,研究组服用帕罗西汀和喹硫平,对照组单用帕罗西汀,疗程均为8周。应用耶鲁-布朗强迫症状量表(Y-BOCS)、汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)于治疗前及治疗后2、4、6、8周末评定疗效,采用副反应量表(TESS)评定副反应。结果研究组治疗总有效率高于对照组,差异有统计学意义(P〈0.05)。治疗结束时两组Y-BOCS、HAMD、HAMA评分均显著下降(P〈0.05或0.01),治疗第6周开始两组间Y-BOCS、HAMD、HAMA评分差异有统计学意义(P〈0.05)。结论帕罗西汀合并喹硫平治疗强迫症可以提高疗效,安全性较好,不会明显增加不良反应。  相似文献   

13.
付叶水 《中国基层医药》2011,18(19):2623-2624
目的观察认知一应对疗法(CCT)联合氯米帕明治疗强迫性神经症的临床疗效。方法42例强迫性神经症患者在知情同意下随机分成对照组和观察组各21例,两组均常规采用氯米帕明治疗,观察组在此基础上采用CCT治疗,采用耶鲁-布朗的Y—BOCS—SC量表对两组治疗前后进行强迫症状评价。结果经治疗后,观察组Y、BSCS.SC评分由治疗前的(24.78±9.01)分降低为(9.74±5.28)分(t=3.17,P〈0.05),对照组由治疗前的(24.82±8.96)分降低为(15.434-4.79)分(t=2.69,P〈0.05);观察组治疗后Y—BSCS—SC评分较对照组治疗后降低更明显(t=2.28,P〈0.05)。治疗1个疗程后,观察组痊愈15例(71.4%)、有效6例(28.6%)、无效0例(0.O),对照组分别为0例(0.0)、2例(9.5%)、19例(90.5%),两组痊愈率、有效率、无效率等差异均有统计学意义(x。=15.29、11.32、14.36,均P〈0.01)。结论CCT联合氯米帕明治疗强迫性神经症有较好的疗效,适合于临床推广。  相似文献   

14.
OBJECTIVE: To evaluate the effectiveness of lithium augmentation of topiramate on mood symptoms, binge eating behavior, and body weight in obese bipolar patients with binge eating disorder (BED) seeking weight management. METHOD: We conducted a naturalistic study of 12 consecutive outpatients with bipolar disorders, BED, and obesity who received lithium augmentation for mood instability during the course of topiramate-based pharmacotherapy for obesity and BED. Lithium was added to topiramate (mean dose 514 mg i.d.) and titrated to a mean dose of 1009 mg i.d. (mean plasma concentration 0.7 mmol/L). Treatment response was assessed by comparing changes in clinical severity scales for mood and eating disorders, weekly binge eating frequency, and weight for the 2 months before and the first 2 months during lithium treatment. RESULTS: A statistically significant improvement in global severity of mood symptoms was observed after as compared to before lithium augmentation. Statistically insignificant reductions in weight and in binge frequency and severity were also observed after lithium addition. CONCLUSION: Optimal weight loss treatment in obese patients with comorbid bipolar and BEDs may require stabilization of mood. The combination of lithium and topiramate may have a role in the management of this difficult-to-treat population.  相似文献   

15.
目的探讨帕利哌酮联合舍曲林治疗强迫症的疗效。方法将符合条件的56例强迫症患者随机分为帕利哌酮联合舍曲林组和单用舍曲林组,各28例,治疗12周。采用耶鲁-布朗强迫量表(Y-BOCS)和副反应量表(TESS)评定疗效和副反应。结果治疗结束后两组Y-BOCS评分均显著降低,而合用组更为明显,与舍曲林组比较差异具有统计学意义(13.18±4.16vs10.56±3.66,t=2.40,P〈0.05)。治疗第6周末时,研究组副反应显著高于对照组(3.56±1.64vs2.68±1.27,t=2.18,P〈0.05),而当治疗第12周末时两组副反应差异无统计学意义(2.83±1.45vs2.47±1.22,t=0.95,P〉0.05)。结论帕利哌酮可以作为舍曲林增效剂治疗强迫症,增强疗效。  相似文献   

16.
Tourette syndrome (TS) and obsessive-compulsive disorder (OCD) both are neuropsychiatric disorders associated with abnormalities in dopamine neurotransmission. Aims of this study were to quantify striatal D2/3 receptor availability in TS and OCD, and to examine dopamine release and symptom severity changes in both disorders following amphetamine challenge.Changes in [11C]raclopride binding potential (BPND) were assessed using positron emission tomography before and after administration of d-amphetamine (0.3 mg kg?1) in 12 TS patients without comorbid OCD, 12 OCD patients without comorbid tics, and 12 healthy controls. Main outcome measures were baseline striatal D2/3 receptor BPND and change in BPND following amphetamine as a measure of dopamine release.Voxel-based analysis revealed significantly decreased baseline [11C]raclopride BPND in bilateral putamen of both patient groups vs. healthy controls, differences being more pronounced in the TS than in the OCD group. Changes in BPND following amphetamine were not significantly different between groups. Following amphetamine administration, tic severity increased in the TS group, which correlated with BPND changes in right ventral striatum. Symptom severity in the OCD group did not change significantly following amphetamine challenge and was not associated with changes in BPND.This study provides evidence for decreased striatal D2/3 receptor availability in TS and OCD, presumably reflecting higher endogenous dopamine levels in both disorders. In addition, it provides the first direct evidence that ventral striatal dopamine release is related to the pathophysiology of tics.  相似文献   

17.
目的 观察团体认知行为治疗改善强迫症患者生存质量的临床疗效.方法 将81例强迫症患者随机分为研究组40例(帕罗西汀+团体认知行为治疗)和对照组41例(帕罗西汀治疗),疗程14周.采用耶鲁-布朗强迫量表(Y-BOCS)、世界卫生组织生存质量量表(WHOQOL)评定临床疗效.结果 治疔14周后两组Y-BOCS均明显下降,两组下降幅度相比差异无显著性(P>0.05).WHOQOL量表评分水平较治疗前有显著改善,且治疗后研究组低于对照组(P<0.05).结论 团体认知行为联合帕罗西汀治疗和单纯帕罗西汀药物治疗均能改善强迫症状,但联合治疗能明显改善强迫症患者的生存质量.  相似文献   

18.
ABSTRACT

The authors report the case of a 32-year-old man who had been treated for anxiety and obsessive-compulsive disorder and had received 800?mg methylphenobarbital (MPB). After switching to a barbiturate-free schedule, his condition continued to be unstable for more than 21 MPB half-lives (approx. 30 days) and did not stabilize until MPB-metabolites dropped below their urinary detection limit. Considering that this article provides findings from a single patient, the authors use this experience to discuss and emphasize the importance of clinical control of barbiturates in psychiatry.  相似文献   

19.
Rationale Recent investigation suggests that a reversible glutamatergically mediated thalamocortical-striatal dysfunction may serve as a reliable pathophysiological and treatment response marker for obsessive-compulsive disorder (OCD). We postulated that N-methyl-d-aspartate (NMDA) receptors were involved in OCD, and specifically that polymorphisms in the 3 untranslated region of GRIN2B (glutamate receptor, ionotropic, N-methyl-d-aspartate 2B) were associated with OCD in affected families.Objectives The objective of this investigation was to test the association between GRIN2B variants and transmission of the OCD trait using a family-based design.Methods Using the Family Based Association Test (FBAT), we tested for association with OCD diagnosis in 130 families, and also performed a haplotype analysis. FBAT was additionally used in a subset of 98 families to test for association with the quantitative phenotype of lifetime OCD symptom severity.Results Under a non-additive model of inheritance, the 5072T/G variant was significantly associated with OCD even after correcting for the number of models tested (P=0.014). In addition, there was a significant positive association with OCD diagnosis (P=0.002) for the 5072G–5988T haplotype under the recessive model.Conclusions Although preliminary and requiring replication in larger samples, these results provide evidence that GRIN2B may be associated with susceptibility to OCD. Coupled with basic neuroscience and clinical neuroimaging findings in patients with OCD, our results provide new and converging support for the role of altered glutamatergic neurotransmission in the pathogenesis of OCD.Earlier versions of this data were previously presented at American Psychiatric Association Annual Meeting, Philadelphia, Pa., USA, May 18–23, 2002; Anxiety Disorders Association of America, Toronto, ON, March 28, 2003.  相似文献   

20.
目的:了解中学生强迫症状的现况,为中学生心理健康维护提供科学依据.方法:采用自编一般情况调查表、SCL-90对学生进行调查.结果:中学生强迫症状,高中生显著高于初中生,女生显著高于男生,农村显著高于城市,家庭经济状况差者显著高于家庭经济状况好者,父母文化程度低者显著高于父母文化程度高者.结论:影响强迫的因素有年龄、性别、家庭经济状况、父母文化程度和生源地,注重开展中学生心理健康教育.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号